Gil Blum

Kaveri Pohlman

Marc Frahm

- Shattuck Laboratories (STTK) is developing **SL325**, a first-in-clinic and potentially first-in-class death receptor three (DR3) blocking antibody, for inflammatory bowel disease (IBD) and other autoimmune diseases.  **[0001680367_2172565_0]** **[0001680367_2172565_1]** **[0001680367_2172565_5]** 
- The company emphasizes that targeting DR3 directly, rather than its ligand TL1A, offers potential advantages including **superior efficacy** due to DR3's stable and broader expression, and **reduced immunogenicity** by avoiding immune complex formation.  **[0001680367_2172565_1]** **[0001680367_2172565_2]** **[0001680367_2172565_4]** **[0001680367_2172565_5]** 
- Shattuck Laboratories expects its **Phase 1 study** for SL325 to be completed in the **first half of 2026**, after which it plans to immediately advance into multiple placebo-controlled Phase 2 trials, including one for IBD.  **[0001680367_2172565_7]** 
- The development of SL325 addresses the significant challenge of avoiding residual agonism, positioning Shattuck Laboratories as the **first to develop a pure DR3 antagonist**.  **[0001680367_2172565_6]** **[0001680367_2172565_7]**

Shattuck Laboratories Discusses DR3 Blocking Antibody Development

- Shattuck Labs, Inc. closed a private placement of up to **$103 million**, with proceeds expected to fund operations into **2029** assuming full exercise of common stock warrants.  **[1680367_0001193125-25-188078_d95844dex991.htm:0]** 
- The financing is anticipated to advance SL-325 through multiple Phase 2 clinical trials, including for Inflammatory Bowel Disease (IBD).  **[1680367_0001193125-25-188078_d95844dex991.htm:0]** 
- The company appointed **Daniel Baker, M.D.**, and **Mona Ashiya, Ph.D.**, to its Board of Directors, while **Tyler Brous, Carrie Brownstein, M.D., Michael Lee, and Kate Sasser, Ph.D.**, resigned.  **[1680367_0001193125-25-188078_d95844d8k.htm:0]** **[1680367_0001193125-25-188078_d95844dex991.htm:0]** **[1680367_0001193125-25-188078_d95844d8k.htm:1]**

Shattuck Labs (STTK)